Evaluating candidate principal surrogate endpoints

Biometrics

Volumn 64, Issue 4, 2008, Pages 1146-1154

  Gilbert, Peter B ^a   Hudgens, Michael G ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b IL   (United States)

Author keywords

Case cohort; Causal inference; Clinical trial; HIV vaccine; Postrandomization selection bias; Prentice criteria; Principal stratification; Structural model

Indexed keywords

BIOMARKERS; BIOMETRICS; MEDICAL APPLICATIONS;

CASE COHORT; CAUSAL INFERENCES; CLINICAL TRIAL; HIV VACCINE; POSTRANDOMIZATION SELECTION BIAS; PRENTICE CRITERIA; PRINCIPAL STRATIFICATION; SELECTION BIAS; STRUCTURAL MODELING; TREATMENT EFFECTS;

VACCINES;

BIOLOGICAL MARKER; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

BIOMARKER; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE TREATMENT; ESTIMATION METHOD; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; SURROGATE METHOD; VACCINE;

ARTICLE; CAUSAL EFFECT PREDICTIVENESS SURFACE; DISEASE MARKER; HUMAN; IMMUNE RESPONSE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; SIMULATION; STATISTICAL ANALYSIS;

EID: 56049086418     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/j.1541-0420.2008.01014.x     Document Type: Article

References (16)

1. Breslow, N. and Day, N. (1980). Statistical Methods in Cancer Research, Volume 1. Lyon, France : International Agency for Research on Cancer.
2. Buyse, M. and Molenberghs, G. (1998). Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54, 1014 1029.
3. Chan, I., Shu, L., Matthews, H., Chan, C., Vessey, R., Sadoff, J., and Heyse, J. (2002). Use of statistical models for evaluating antibody response as a correlate of protection against varicella. Statistics in Medicine 21, 3411 3430.
4. Follmann, D. (2006). Augmented designs to assess immune response in vaccine trials. Biometrics 62, 1161 1169.
5. Frangakis, C. and Rubin, D. (2002). Principal stratification in causal inference. Biometrics 58, 21 29.
6. Freedman, L., Graubard, B., and Schatzkin, A. (1992). Statistical validation of intermediate endpoints for chronic diseases. Statistics in Medicine 11, 167 178.
7. Gilbert, P., Peterson, M., Follmann, D., Hudgens, M. G., Francis, D. P., Gurwith, M., Heyward, W. L., Jobes, D. V., Popovic, V., Self, S. G., Sinangil, F., Burke, D., and Berman, P. W. (2005). Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. Journal of Infectious Diseases 191, 666 677.
8. Halloran, M. and Struchiner, C. (1995). Causal inferences in infectious diseases. Epidemiology 6, 142 151.
9. Huang, Y., Pepe, M., and Feng, Z. (2007). Evaluating the predictiveness of a continuous marker. Biometrics 63, 1181 1188.
10. Pepe, M. and Fleming, T. (1991). A non-parametric method for dealing with mismeasured covariate data. Journal of the American Statistical Association 86, 108 113.
11. Prentice, R. (1986). A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73, 1 11.
12. Prentice, R. (1989). Surrogate endpoints in clinical trials: Definition and operational criteria. Statistics in Medicine 8, 431 440.
13. Robins, J. (1995). An analytic method for randomized trials with informative censoring: Part I. Lifetime Data Analysis 1, 241 254.
14. Rubin, D. (1986). Statistics and causal inference: Which ifs have causal answers. Journal of the American Statistical Association 81, 961 962.
15. Taylor, J., Wang, Y., and Thiebaut, R. (2005). Counterfactual links to the proportion of treatment effect explained by a surrogate marker. Biometrics 61, 1102 1111.
16. Weir, C. and Walley, R. (2006). Statistical evaluation of biomarkers as surrogate endpoints: A literature review. Statistics in Medicine 25, 183 203.